Evidence map›Paper›PMID 32748838›Full record

ArticleCancers2020

Quercetin-Resveratrol Combination for Prostate Cancer Management in TRAMP Mice.

Chandra K Singh, Gagan Chhabra, Mary A Ndiaye, Imtiaz A Siddiqui, Jennifer E Panackal, Charlotte A Mintie, Nihal Ahmad

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. The multifaceted role of insulin-like growth factor binding protein 7.Frontiers in cell and developmental biology · 2024
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chandra K SinghDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.ORCID 0000-0003-3505-0350
Gagan ChhabraDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.
Mary A NdiayeDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.ORCID 0000-0002-5254-1840
Imtiaz A SiddiquiDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.
Jennifer E PanackalDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.
Charlotte A MintieDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.
Nihal AhmadDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.ORCID 0000-0002-4239-9887
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Role of Polo-Like Kinase-1 in Melanocytic TransformationR01AR059130 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI AHMAD, NIHAL · 2010 to 2019
$3.8M
Skin Diseases Research Center at the University of WisconsinP30AR066524 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI WOOD, GARY S · 2014 to 2018
$2.6M
Role of SIRT1 in melanocyte biology and melanocyte transformationR01CA176748 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AHMAD, NIHAL · 2013 to 2017
$1.6M
BLRD VA I01 BX004221BLRD VA IK6 BX003780CSRD VA I01 CX001441NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA176748NIAMS NIH HHS P30 AR066524NIAMS NIH HHS P30AR066524NIAMS NIH HHS R01 AR059130NIH HHS R01AR059130, R01CA176748U.S. Department of Veterans Affairs I01CX001441, I01BX004221, IK6BX003780
6 · The paper itself

Abstract

Prostate Cancer (PCa) is a leading cause of cancer-related morbidity and mortality in men. Therefore, novel mechanistically-driven approaches are needed for PCa management. Here, we determined the effects of grape antioxidants quercetin and/or resveratrol (60 and 600 mg/kg, respectively, in diet) against PCa in Transgenic Adenocarcinoma of Mouse Prostate (TRAMP)-model in prevention and intervention settings. We found resveratrol alone and in combination significantly inhibited prostate tumorigenesis in prevention setting, while the same was seen only in combination after intervention. The observed effects were associated with marked inhibition in proliferation, oxidative stress, and tumor survival markers, and induced apoptosis markers. Utilizing PCa PCR array analysis with prevention tumor tissues, we identified that quercetin-resveratrol modulates genes involved in promoter methylation, cell cycle, apoptosis, fatty acid metabolism, transcription factors, androgen response, PI3K/AKT and PTEN signaling. Ingenuity Pathway Analysis (IPA) identified IGF1 and BCL2 as central players in two gene networks. Functional annotation predicted increased apoptosis and inhibited cell viability/proliferation, hyperplasia, vasculogenesis, and angiogenesis with dual treatment. Furthermore, IPA predicted upstream inhibition of major PCa signaling VEGF, Ca

Indexed as

chemopreventiongrape antioxidantsprostate cancerquercetinresveratrol

Identifiers

PMID32748838
PMCPMC7465013
OpenAlexW3046832830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.